In collaboration with the National Institutes of Health (NIH), Banner Alzheimer’s Institute (BAI), University of Antioquia in Colombia and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announce the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. This groundbreaking study—the first to investigate whether an anti-amyloid treatment can stave off the disease—will span two countries and help launch a new era of prevention research in the urgent fight against Alzheimer’s.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56128-banner-alzheimer-s-institute-genentech-nih-prevention-trial-genetics
Caralluma
Fimbriata is widely acknowledged as the MOST POWERFUL weight loss and
appetite suppressant that is completely natural and 100% side effect
free! To learn all about Caralluma and what it means for YOU CLICK http://carallumaforyou.com/ To learn about the bestselling Caralluma product CLICK http://carallumaforyou.com/caralluma-actives
College Student Blogs. Click This Link: http://www.Bempowered2.com Enter Your Email...Watch The FREE VIDEO! http://youtu.be/zD6guFvx0No https://www.facebook.com/note.php?note_id=387848464582218
Installing child restraints can frustrate even the most capable of parents. A system called Lower Anchors and Tethers for Children is supposed to make things easier by standardizing attachment hardware, but a new study shows that many automakers aren’t paying attention to the key factors that make LATCH work. Only 21 of the 98 top-selling 2010-11 model passenger vehicles evaluated have LATCH designs that are easy to use. This is the main finding of joint research conducted by the Insurance Institute for Highway Safety and the University of Michigan Transportation Research Institute (UMTRI).
Nearly five black women die needlessly per day from breast cancer in the United States – a total of 1,722 deaths annually – according to a study released today at the Avon Foundation Breast Cancer Forum and simultaneously published in Cancer Epidemiology. The 2012 Racial Disparity in Breast Cancer Mortality Study found that 21 of the 25* largest U.S. cities have a black: white disparity in breast cancer mortality, 13 of which are statistically significant.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52895-avon-foundation-breast-cancer-forum-racial-disparity-mortality-study
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
According to a national study released today, moms are feeling overwhelming pressure to overspend on products for their babies even as they significantly cut back in nearly every other area of their lives to cope with these challenging times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54418-kelton-research-mom-study-baby-products-store-brand-infant-formula
Northwestern Mutual’s latest Cost of Long-Term Care study, released today, reveals consistently high costs for home health care, assisted living and nursing home care across the nation, underscoring the critical need to address long-term care as part of financial security planning.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53641-northwestern-mutual-cost-of-long-term-care-study-caregiving
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
